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Abstract
Traumatic brain injury leads to cellular damage which in turn results in the rapid release of damage-associated molecular
patterns (DAMPs) that prompt resident cells to release cytokines and chemokines. These in turn rapidly recruit neutrophils,
which assist in limiting the spread of injury and removing cellular debris. Microglia continuously survey the CNS (central
nervous system) compartment and identify structural abnormalities in neurons contributing to the response. After some
days, when neutrophil numbers start to decline, activated microglia and astrocytes assemble at the injury site—segregating
injured tissue from healthy tissue and facilitating restorative processes. Monocytes infiltrate the injury site to produce
chemokines that recruit astrocytes which successively extend their processes towards monocytes during the recovery phase.
In this fashion, monocytes infiltration serves to help repair the injured brain. Neurons and astrocytes also moderate brain
inflammation via downregulation of cytotoxic inflammation. Depending on the severity of the brain injury, T and B cells can
also be recruited to the brain pathology sites at later time points.
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Background
Traumatic brain injury (TBI) results from force transmission
to the head either by impact with an object or from acceler-
ation/deceleration forces that produce vigorous movement
of the brain within the skull or varying combinations of these
mechanical forces [1]. It is now widely acknowledged that
TBI is a multimodal complex disease process and not a sin-
gle pathophysiological event [2]. It triggers structural and
functional changes leading to neuronal injury which can be
classified into primary and secondary brain injury [3]. Pri-
mary injury is caused by external forces (direct contact and/
or inertial forces to the brain) acting at the moment of the
injury that damages the blood vessels, axons, nerve cells, and
glia of the brain in a focal, multifocal, or diffuse pattern of in-
volvement. The type and severity of the resulting injury de-
pends upon the nature of the original force plus the site,
direction, and magnitude of the force [4]. In contrast, sec-
ondary injury is an ongoing process that occurs from
minutes to years following the initial insult. Secondary injury
is the result of the cascades of metabolic, neurochemical, cel-
lular and molecular events stemming from primary insult
[5]. Such mechanisms ultimately lead to brain cell death,
plasticity, tissue damage and atrophy [6–8]. Some of the bio-
chemical alterations responsible for secondary injury are (i)
perturbation of cellular calcium homeostasis, (ii) glutamate
excitotoxicity, (iii) mitochondrial dysfunction, (iv) increased
free radical generation, (v) inflammation, (vi) increased lipid
peroxidation, (vii) apoptosis, (viii) diffuse axonal injury (DAI)
and (ix) blood-brain barrier breakdown [9]. Of note, all of
the above-listed factors can be linked to neuroinflammation
either directly or indirectly, and such inflammation has been
implicated in both the early and chronic components of
TBI-induced neuropathology [10–12].
Damaged neuronal tissue releases chemokines which in
turn recruit immune cells to the area of injury [13, 14]. De-
pending on the nature of the insult, traumatic contusion, dif-
fuse injury or raised intracranial pressure can contribute to
the resulting inflammatory response, with potentially distinct
cellular patterns. In focal injury (experimental animal
models), the infiltration of neutrophils appears early peaking
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within a few days followed by the migration of microglia/
macrophages, astrocytes and lymphocytes to the site of injury
[15]. In a focal drop device model in rats, Al Nimer et al. re-
ported a 10- to 20-fold increase in the numbers of microglia
as compared to the peripheral macrophages, suggesting the
occurrence as a central rather than peripheral response [16].
In diffuse injury, preclinical studies report little to no neutro-
phil infiltration, with the early cellular response consisting of
microglial accumulation and astrocytosis most prominent in
the white matter tracts [17]. In a recent study, we observed
differential downstream production of cytokines in enriched
human cortical neuronal cultures exposed to similar levels of
cytokines seen in the brain following human TBI, which may
modify pathophysiological processes in both beneficial and
detrimental ways in the in vivo situation. Our finding
suggests that IL (Interleukin)-1β induced a limited cytokine
response in neurons which may echo a relative paucity
of IL-1 receptors (IL-1r) on the neuronal population
[18]. In a follow-up study using a similar approach,
enriched iPSC (induced pluripotent stem cells)-derived
astrocytic cultures exposed to escalating concentrations
of different cytokines generate an increased production
of downstream cytokines, particularly when exposed to
IL-1β [19].
Following TBI, the cytokine response comes from the
diverse immunocompetent cell types such as microglia,
astrocytes, cerebrovascular endothelial cells, peripheral
immune cells, and even neurons. As such, the inflam-
matory response is signalled by a rapid rise in cytokines
and chemokines [20–23]. After a moderate diffuse-TBI
in mice, levels of typical pro-inflammatory cytokines
such as IL-1β, tumour necrosis factor (TNF) and IL-6
within the cortex peak at 3-9 h before gradually dimin-
ishing [24]. Similarly, within clinical studies, increased
levels of IL-6, TNF, IL-10, C-C motif chemokine ligand
2 (CCL2) and IL-8 peak within the first 2 days following
brain injuries and then return to normal over several
weeks [23, 25, 26]. This spike in cytokine release has
been correlated with astrogliosis, microglial activation
and axonal dysfunction, providing evidence of the as-
sociation between the activated immune response and
brain pathology [27]. We have reported both a dose-
and/or time-dependent release of cytokines in our
enriched human neuronal culture model of injury
[19]. The IL-6 and TNF exposure each resulted in
significantly increased levels of more than 10 cyto-
kines over time, whilst IL-1β increased the level of
C-X-C motif chemokine-10 (CXCL10/IP10) alone.
Importantly, these patterns are consistent with our
previous in vivo human TBI data [28], thus validating
our human stem cell-derived neuronal platform as a
clinically useful reductionist model. In the present re-
view, we will discuss the role of cellular infiltration
in inflammation after TBI.
Mechanisms of cellular infiltration after TBI
DAMPs and innate immunity
The innate immune system is a complex network of cells
and signalling mediators that serves as the first line of
defence against invading pathogens and injuries. In the
case of TBI where the initial mechanical trauma causes
direct damage, it is the microglia and astrocytes that ini-
tiate a cascade of immune events directed by the release
of damage-associated molecular patterns (DAMPs) [29,
30]. The stimulation of nonspecific immune responses
results in the recruitment of mononuclear phagocytes
(MP; peripheral monocyte-derived macrophages and
neutrophils) into the brain from the blood whilst activat-
ing resident glia (Fig. 1). These cells produce an array of
pro-inflammatory mediators, reactive oxygen species
(ROS) and pro-apoptotic proteins that perpetuate neural
injury. The complexity of the innate immune response
following TBI is demonstrated by the fact that more
than one hundred genes related to inflammation and
markers of microglia and astrocyte activation were sig-
nificantly upregulated following controlled cortical im-
pact (CCI) in mice [31].
Key cytokines and chemokines
Cytokines are inflammatory regulators that are produced
by systemic leukocytes, glial (astrocytes and microglia)
cells and possibly by neurons [32]. These proteins (cyto-
kines) are traditionally categorised as pro- or anti-
inflammatory in action, although more recently this view
has been nuanced, and they are now often classified into
several families based on their receptor interactions.
Many of these cytokines have been shown to play a role
in brain injury and have been previously reviewed else-
where [22]. When injury occurs to the brain, it activates
the release and production of cytokines and chemokines
which, in turn, trigger receptors resulting in local and
systemic immune responses [33–35]. The net effect of
these innate inflammatory mediators is aimed at limiting
the spread of the injury and restoring homeostatic bal-
ance [36]. Here, we review five important cytokines/che-
mokines below that have been highlighted in the current
TBI literature.
Interleukin-1
The interleukin-1 family (IL-1 family) is a group of 11
cytokines playing a central role in the regulation of im-
mune and inflammatory responses to infections or ster-
ile insults. IL-1α, IL-1β, IL-1ra, IL-18, IL-33, IL-36α, IL-
36β, IL-36γ, IL-36Ra IL-37 and IL-38 have been charac-
terised in this group [37]. Interleukin-1 is primarily an
active pro-inflammatory cytokine protein that has been
associated with various inflammatory and neurological
conditions and is likely one of the first immune mediator
peaks just after the injury. Increased IL-1 production/
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secretion has been shown to aggravate neuroinflamma-
tion and neurodegeneration in the brain, therefore, pro-
duction/secretion of IL-1 must be regulated firmly [38].
Within the IL-1 family, two distinct forms, IL-1α and
IL-1β play a critical role in inflammatory signals follow-
ing the engagement of IL-1 receptor (IL-1R). Both IL-1α
and IL-1β, although isolated from two distinct comple-
mentary DNAs, induce almost identical downstream in-
flammatory responses but their activation requirements
differ. IL-1α is essentially expressed by nucleated cells
and discharged IL-1α can broadcast inflammatory signal-
ling without further modification/processing. In contrast,
IL-1β is produced in the form of a biologically inactive
protein that needs cleavage to exhibit its inflammatory
properties and secretion [39]. Levels of IL-1β have been
shown to rise after brain injury and as such it is one of
the most frequently measured cytokines in TBI research
[40–53]. After brain injury, IL-1β is known to strongly
enhance inflammatory responses and has profound
effects on BBB (blood-brain barrier) permeability, glial
activation, immune cell recruitment and ultimately in
neurodegeneration [54–56]. To summarise, IL-1 produc-
tion may negatively impact clinical outcomes following
TBI [49].
Several recent methods have been trialled in human dis-
ease to neutralise/antagonise the activity of IL-1β in brain
injury. Anakinra, a recombinant IL-1rreceptor antagonist
(IL-1ra), is currently being tested to treat severe TBI in
humans, as it has shown promise in the treatment of
stroke by Emsley and coworkers [57]. Clausen and
Fig. 1 Timeline of cellular response after TBI. a Upon TBI, cellular damage results in the rapid release of damage-associated molecular patterns (DAMPs) that
prompt resident cells to release cytokines and chemokines. These signals quickly recruit neutrophils, which aid in the containment of the injury site and promote
the removal of debris and damaged cells. As neutrophil numbers begin to decline after days, infiltrating monocytes and activated microglia and astrocytes begin
to accumulate around the site of injury to perform reparative functions. Depending on the severity of the brain injury, T and B cells can also be recruited to sites
of brain pathology at later time points in the response (5-7 days post-injury). Severity of the brain damage (red dashed) depends on the secondary injury mainly
caused by the fluctuating microglia especially the M1-type (neurotoxic) microglia as shown by green dashed lines. b Schematic representation to highlight the
behaviour of cells after TBI
Alam et al. Journal of Neuroinflammation          (2020) 17:328 Page 3 of 17
colleagues [58, 59] in their studies showed that the admin-
istration of anti-IL-1β neutralising antibody to CCI-
injured animals for 14 days after TBI resulted in decreased
numbers of macrophages/microglia, neutrophils and T-
cells in the brain, especially at day 7 after injury. We have
carried out a randomised controlled trial of Anakinra and
utilised principal component analysis (PCA) to demon-
strate that IL-1 signalling is a key upstream regulator of
TBI-induced cytokines/chemokines production [60].
Later, we have also shown that recombinant IL-1ra pro-
motes macrophages to express higher levels of pro-
inflammatory cytokines such as granulocyte-macrophage
colony-stimulating factor (GM-CSF) and IL-1β [61]. We
demonstrated that treatment with Anakinra causes a
brain-specific modifications of the cytokine/chemokine re-
sponse in the first 48 h following injury [61]. The scale of
this response is dependent on the IL-1ra concentration
achieved in the brain extracellular fluid (ECF). In
Anakinra-treated patients, chemokines related to recruit-
ment of macrophages biassed towards M1-type microglia
are increased. On the other hand, cytokines/chemokines
biassed towards M2-type microglia are relatively increased
in control patients. Against this background, it is clear that
the simplistic classification of cytokines such as IL-1ra as
an anti-inflammatory cytokine may not sufficiently cap-
ture the complexity of its role in neuroinflammation fol-
lowing brain injury.
Interleukin-6
Interleukin-6 (IL-6), a 26 kDa glycoprotein, is a main ef-
fector of the acute phase response. Its receptor is a gp130
homodimer with a ligand-specific a-subunit. Binding of
IL-6 induces dimerization of the receptor and activation
of the JAK-STAT (Janus kinase-signal transducers and ac-
tivators of transcription) intracellular pathway that regu-
lates transcription of target genes within the cell nucleus
through the nuclear translocation of phosphorylated
STAT3 [62]. In humans, interleukin-6 has often been cor-
related with TBI outcome, but it is ambiguous whether its
role is predominantly beneficial or detrimental. Brain ECF
(extracellular fluid) detection of raised parenchymal IL-6
levels, using microdialysis, has been correlated with im-
proved survival in brain injury patients [63]. Kumar and
coworkers [50] showed that both subacute and chronic
serum levels of IL-6 have correlated with unfavourable
short and long-term consequences after TBI. In a follow-
up study assaying IL-6 in human cerebrospinal fluid (CSF)
and separating human patients by (high or low) CSF IL-6
trajectories, high trajectory patients were much more
likely to have an adverse clinical aftermath [50]. Recent
evidence by Liao et al. [64] in plasma suggests a detrimen-
tal role for IL-6 in human brain injury. These investigators
showed that plasma levels of IL-6 were considerably
higher in severe TBI patients than moderate TBI patients.
The difference between these studies reflects the import-
ance of recognising that distinct biological compartments
(plasma vs CSF vs brain ECF) may represent distinct in-
flammatory responses and the additional contribution of
extra-cranial injuries. Therefore, whilst a unitary role for
IL-6 in brain injury across these compartments cannot be
gleaned, evidence from TBI patients reveals that IL-6 is
steadily upregulated after injury and can remain high in
chronic stages, making it a potential mediator of long-
term outcome.
Tumour necrosis factor
Tumour necrosis factor (TNF) regulates many key pro-
cesses in the central nervous system, including neuronal
development, cell survival, synaptic plasticity, and ionic
homeostasis. Furthermore, TNF acts as a major coordin-
ator of the inflammatory response and dysregulated
TNF signalling has been implicated in the pathophysi-
ology of several CNS conditions, specifically relating to
leukocyte infiltration [65] and increased BBB permeabil-
ity [66]. In in vitro models, TNF acts synergistically with
IL1 [67] and both are thought to act through similar
intracellular transduction pathways [68].
Initial work on the role of TNF in TBI mouse models
suggested that it has early harmful effects post-TBI
whilst demonstrating more protective roles in chronic
stages [69]. However, Stahel et al. [70] suggested that
TNF is essential to protection from early mortality
within the first week from injury. Irrespective of these
seemingly contradictory studies, TNF consistently shows
upregulation after brain injury, advocating an important
role of TNF in both the acute and chronic stages [47, 49,
64, 71].
More recently, in a weight drop animal model, the im-
portance of TNF early after injury was established. Baratz
et al. [72] in their study demonstrated that mice that were
given TNF inhibitor at 1 and 12 h post-injury showed im-
proved cognitive performance 7 days post-injury, but the
animals administered the inhibitor at 18 h post-injury did
not. This suggests a very narrow window for TNF-
targeting therapeutics after brain injury. Additional inves-
tigation showed that mice injected with TNF-inhibitor at
1 h showed fewer apoptotic neurons and less astrogliosis
at 72 h post-injury in both the cortex and dentate gyrus.
This study defined a 12 h window after an injury during
which the negative effects of TNF may be attenuated, and
points towards a tentative link between TNF and pro-
longed astrogliosis and neuronal death.
Interleukin-10
IL-10 is an established anti-inflammatory cytokine with
potent immunomodulatory effects. Knoblach and Faden
[73] examined the effect of IL-10 using diverse adminis-
tration paradigms in relation to TBI. When administered
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to rats intravenously (iv) at 30 min before and 60min
after a lateral fluid percussion (LFP) injury model, IL-10
resulted in superior neurological recovery after brain in-
jury. This administration strategy also decreased the
amount of IL-1β and TNF in the brain. When adminis-
tered subcutaneously (sc) at 10 min, 1, 3, 6, 9 and 12 h
after trauma, neurological recovery was improved at 7
days but the effect diminishes at 14 days. Interestingly,
IL-10 showed no effect when administered by intra-
cerebroventricular (icv) injection, suggesting the benefi-
cial effects are mediated via the peripheral immune sys-
tem. Kline et al. [74] found that after CCI, whilst
systemic administration of IL-10 decreases the number
of neutrophils hoarding in the parenchyma, it did not
advance behavioural effects and reduced the neuropro-
tective effect of hypothermia.
It has been shown that interleukin-10 elevated in brain
injury patients [45, 75–77], and has also been associated
with unfavourable outcome and mortality [49, 76, 77].
Despite this, Chen et al. [41] uncovered the role of IL-10
in conferring neuroprotection with hyperbaric oxygen
(HBO) treatment. They found that the protective effects
of HBO in TBI included decreased lesion volume and
oedema, improve cognition and diminishing pro-
inflammatory cytokine production in the cortex follow-
ing controlled cortical impact in wild-type mice vs IL-
10-knockouts. This led to a shift from apoptotic to cell
survival traits and superior BBB integrity. The link be-
tween IL-10 (and other cytokines) and poor outcome
may be confounded by the widespread upregulation of
cytokines after TBI.
Transforming growth factor β
TGF-β, a 28-kDa dimeric protein, consists of two 14-
kDa subunits and is produced by various cell types in-
cluding T-cells and monocytes [78, 79]. TGF-β is pleio-
tropic in its action. It can restrict the growth of many
cell types and also induce the secretion of the extracellu-
lar matrix. It can also antagonise many immune re-
sponses such as T cell and macrophage activation.
Transforming growth factor-β rises acutely in the serum
and CSF of TBI patients [80]. In several TBI models,
TGF-β signalling mediators are upregulated [53, 81, 82].
Zhang et al. [53] showed that after weight drop TBI,
TAK1 (transforming growth factor beta-activated kinase
1) increased in expression and was detected in cortical
neurons as well as in astrocytes. Inhibition of TAK1 sig-
nalling diminishes NF-κB activity and inflammatory
cytokine release which, in turn, improves the neuronal
survival and motor functions. TGIF (a transcriptional
co-repressor of TGF-β) can inhibit transcriptional acti-
vation of TGF-β. After knocking down TGIF levels in
the brain by small hairpin RNA (ribonucleic acid), Chio
and colleagues discovered that the drop in TGIF levels
led to a reduction in infarct volume and microglia cell
number around the region of induced TBI along with
the noticeable modification in microglial morphology
[81]. Chio et al. [81] found that knocking down TGIF
improves motor function through 2 weeks post-injury.
These data prove that mediators of TGF-β signalling can
have important inflammatory consequences.
Blood-brain barrier
The BBB is a complex structure that is involved in the
pathogenesis of brain injury. It is formed by the neuro-
vascular unit, the conjunction of cerebrovascular endo-
thelial cells, pericytes, astrocytes and the basal lamina
[83]. The BBB firmly regulates the exchange of all sub-
stances between plasma and the brain interstitium ex-
cept small lipophilic molecules. Ion homeostasis and
uptake of small molecules into the brain (e.g. glucose
and amino acids) is conducted through specific endothe-
lial membrane channels and solute carriers. Larger pro-
teins and peptides are transported by endo-/trans-cytosis
pathways within caveolae and clathrin-coated microvesi-
cles. Notably, paracellular diffusion is greatly restricted
by tight junctions amongst the apical regions of adjacent
endothelial cells [83].
The brain is a highly vascularized organ for the effi-
cient intake of oxygen and nutrients. Approximately
20% of the body’s total energy consumption takes
place here [84]. In continuous and close contact with
neurons and glia, the BBB is one of the most vital
sites controlling the CNS microenvironment and
homeostasis. It fulfils two main functions: (i) a phys-
ical barrier and (ii) a selective exchange barrier.
Whilst the BBB has long been seen as a firm wall
protecting the CNS, recent evidence reveals that this
barrier is a lot more plastic and pliable than previ-
ously assumed. For decades, the immune privilege of
the CNS perceived as an absence of immune system
inside the CNS, and BBB was considered as the only
barrier separating the CNS from the peripheral im-
mune system and so preventing entry of infectious
agents and immune cells [85]. Widespread work in
the last decade unravelled the presence of a very spe-
cialised intrinsic innate immune system in the CNS
[86]. This was supplemented by several observations
showing that BBB is not just a passive barrier from
an immunological point of view, but rather plays an
active role in the immune response of the CNS [87].
Trauma to the brain results in disruption of the BBB,
assisting recruitment of circulating neutrophils, mac-
rophages and lymphocytes to the injured site [88].
The increase of systemic immune cells within the
brain parenchyma has been reported in human TBI
as well as animal models of brain trauma [89]. These
cells release inflammatory mediators that direct glia
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and immune cells to the injury site. In addition to
the infiltrating immune cells, the activation of resi-
dent microglia plays a major role in response to brain
injury [90] (Fig. 2).
Meninges
During inflammation, the entry of immune cells to the
CNS parenchyma is secondary to their infiltration into
the meninges [91]. Therefore, it is important to identify
the mechanisms by which immune cells cross the men-
inges. Two plausible routes might explain how immune
cells access the meninges: (i) through the meningeal
blood vessels or (ii) via the choroid plexus (CP). The
choroid plexus is located within each ventricle of the
brain and is composed of epithelial cells surrounding the
capillaries and stromal cells. The endothelial cells in the
choroid plexus are fenestrated in the CNS [92]. The role
of choroid plexus epithelial cells is to produce cerebro-
spinal fluid (CSF) by selectively extracting blood constit-
uents, resulting in the highly vascularized choroid
plexus, allowing the presence of many immune cells.
However, this does not necessarily mean that cells can
penetrate the epithelial layer and thus gain entry into
the meningeal spaces or CSF. To access the meninges,
immune cells from blood vessels supplying the choroid
plexus need to cross the endothelial barrier and then the
choroid plexus epithelial cell barrier with tight gap junc-
tions to enter the CSF. For a cell to penetrate the menin-
geal vessels and enter the CSF, it has to cross the blood-
meningeal barrier (BMB). The BMB differs from the
BBB (blood-brain barrier) and lacks some components
such as astrocyte end-feet, thus making it easier for cells
to penetrate [93, 94].
A recent study suggests that meningeal blood vessels recruit
T cells into the meningeal spaces [91]. Through activation of
T cells in the meninges and their detachment are probably
necessary for the cells to access the parenchyma; the route
from the meningeal spaces/CSF to the parenchyma is not
well understood. Meningeal cells can transmigrate across pia
mater to reach the parenchyma [95], but the mechanisms
guiding such a process are still unclear. Under neuro-
inflammatory conditions, the gradient of chemokines pro-
duced and induced by meningeal immune cells might result
in the transmigration of immune cells across the BBB [96].
Fig. 2 Cellular infiltration after TBI. a In healthy brain, the functional unit constituted by firmly coupled endothelial cells and astrocytic end-feet frame
the blood-brain barrier (BBB). Immune cells flow unreservedly in the blood vessel, and in the brain parenchyma, blood-borne and brain-borne proteins
cannot pass into the other compartment, resting microglia survey the intact brain ecosystem. b Following TBI, the BBB disrupted/leaked activating the
endothelial cells. The tight junctions between endothelial cells perish. This allows immune cells to adhere at the blood vessels lamina and then
transmigration to the brain parenchyma. Specific brain proteins (e.g. S100B) are released into the blood according to their concentration gradient in
exchange, serum protein enters the brain parenchyma which has been demonstrated in the cartoon. Now, microglia switch from their resting state to
an activated state, embracing a phagocytic phenotype and secreting pro-inflammatory proteins. Upregulation of adhesion molecules in cerebral vessels
and production of chemokines by activated microglia and astrocytes finally cause blood leukocytes to migrate into the brain parenchyma where
monocytes are suggested to cause additional damage to the brain
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Cellular subtypes
Neutrophils
Neutrophils are the most prevalent leukocytes in the
blood, generated at a rate of ~ 2 × 1011 cells/day within
the bone marrow [97]. In response to inflammation, when
neutrophils come in contact with endothelium they get
activated and express integrins. Integrins, in turn, bind ad-
hesion molecules on the surface of the neutrophil to form
contacts with the endothelium. Following this, integrins
expressed on neutrophils bind to intracellular adhesion
molecule (ICAM-1 and -2) to form a firm adhesion [98,
99]. Once a strong bond is established, trans-endothelial
migration occurs which allows entry of the neutrophils
into the damaged tissue where they perform phagocytic
and clearance functions [100]. In animal models, the earli-
est cells that enter the site of neural injury are neutrophils,
which appear within minutes and peak 2 h later in the
subarachnoid and subdural spaces [98, 101]. Infiltration
into the brain parenchyma peaks 24 to 48 h in the course
of the inflammatory cascade after cortical injury [98, 102]
then decreases substantially over an ensuing 7 days [59,
103, 104].
Few studies have been conducted investigating neutro-
phil dynamics in clinical TBI as the cells are only present
in the hyper-acute/acute phase. Histopathological ana-
lyses have shown they are also few and present only at
the earliest stages of brain injuries. Notably, in brain tis-
sue collected from post-mortem TBI, neutrophils can be
regularly observed in the first hours following injury,
though there is evidence that the cells can enter the
brain in minutes [105]. A comprehensive study including
brains from 305 post-traumatic autopsy cases found evi-
dence of neutrophil infiltration in approximately 43% of
samples from 5min after injury [106]. These data sug-
gest that neutrophil recruitment following injury is a sig-
nificant early event in TBI pathogenesis.
Neutrophil toxicity
Neutrophil infiltration also appears to be a mechan-
ism for protecting the brain in injury states although
neutrophils are toxic to neurons. Neutrophils are
vigorously recruited to the damaged brain when there
is potential infection: strong neutrophil infiltration is
observed in the LPS (lipopolysaccharides)-injected
brain or contusion-injured spinal cord, but not in the
ATP (adenosine triphosphate)-injected brain or
laceration-injured spinal cord [107–109]. Neutrophils
are the first-responder cells that enter damaged tissue
to protect the body from potential infection. Thus,
they express cytotoxic inflammatory mediators, like
iNOS (inducible nitric oxide synthase) and MPO
(Myeloperoxidase). Neutrophils also express cytotoxic
inflammatory mediators in the injured brain [109].
Blood-brain barrier break down
Neutrophils can break down the blood-brain barrier by
releasing metalloproteinases, proteases, TNF and ROS.
After brain injury, the release of inflammatory mediators
can assist this process by inducing a hyper-activated
state that permits neutrophils to break the BBB and
enter the CNS [110]. On arrival, neutrophils have the
power to inflict neuronal cell death exploiting the same
soluble mediators that break down the BBB [111]. Liao
et al. [106] revealed that neutrophils are the most abun-
dant circulating cells after TBI and cause amplified ex-
pression of oxidative enzymes indicative of activation
[64]. Both in the immediate aftermath of TBI as well as
after some days following injury, studies have shown that
relative to healthy control values, both the absolute
number and frequency of circulating neutrophils are sig-
nificantly increased, with Rhind and coworkers [112]
reporting a 4.5-fold elevation in neutrophil numbers as
early as 3 h post-TBI.
Neutrophilia after TBI
This immediate neutrophilia is thought to result from
TBI-induced increases in serum catecholamines and glu-
cocorticoids. A surge in catecholamines will trigger the
entry of marginated neutrophils into the circulation,
whilst a rise in glucocorticoid levels increase the size of
the peripheral neutrophil pool by stimulating their re-
lease from bone marrow stores and by extending their
lifespan and preventing circulating neutrophils from
returning to the bone marrow for clearance [113].
Neutrophil and ROS generation
In contrast to the enhanced ROS generation that charac-
terises the initial response to TBI, neutrophils exhibit im-
paired ROS generation in the days following injury [114].
In a study of hospitalised TBI patients with moderate or
severe brain trauma, Marks et al. [115] found that neutro-
phil ROS production on day 9 post-injury was significantly
lower than that of healthy age- and sex-matched controls.
Given that peak incidences of infection in hospitalised
TBI patients occur 5–11 days after injury, and neutrophils
are the first line of defence against rapidly dividing bac-
teria, fungi and yeast, then impaired ROS generation may
be one mechanism underlying the increased susceptibility
of hospitalised TBI patients to infection [116]. Keeping
this in mind, a comparison of ROS generation between
neutrophils isolated from non-infected and infected TBI
patients revealed a significantly greater percentage of ROS
producing cells in the uninfected group on day 6 post-
injury [115].
Monocytes
Monocytes are a heterogeneous population of blood-
borne leukocytes comprising about 5–10% of circulating
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immune cells. Liao et al. [64] showed that brain injury
leads to an increase in the absolute number of circulat-
ing monocytes [112]. Their study revealed that the in-
crease in monocytes is 2.7-fold higher relative to healthy
controls within 24 h of injury. Post-TBI, this increase in
monocyte number reflects the augmentation of specific
subsets outline in the surface phenotype of circulating
monocytes. In the injured brain, the role of monocytes is
similar to microglia. Monocyte activation is classified as
classical (bactericidal) and alternative (reparative). When
monocytes are exposed to classical activators (e.g. IFN-γ,
CCL2) they produce significant amounts of cytotoxic
inflammatory mediators including reactive oxygen spe-
cies (ROS) and TNF. In contrast, monocytes activated by
interleukins (IL-4 and IL-13) express reparative genes,
comprising mannose receptors [117]. However, accord-
ing to Chen et al. [118], monocytes invading the brain
parenchyma in response to the traumatic brain injury
have a detrimental effect on neuronal survival and func-
tional recovery. The influx of these inflammatory cells is
driven by monocyte chemo-attractants (especially CCL2)
whose synthesis is rapidly increased after brain injury
[26, 119]. In a 2012 study, Szmydynger-Chodobska et al.
[120] demonstrated that neuro-trauma also results in a
rapid increase in the production of CCL2 by the lateral
ventricle choroid plexus (CP) located ipsilaterally to in-
jury. The increase in choroidal CCL2 synthesis was not
associated with post-traumatic accumulation of mono-
cytes in the choroidal tissue but resulted from the pro-
duction of CCL2 by the choroidal epithelium [120].
Their results were consistent with a previous study by
Colotta et al. [121], which showed that although mono-
cytes can produce CCL2 in response to pro-
inflammatory mediators; these inflammatory cells were
rarely found in the ipsilateral choroid plexus (CP) at 6 h
post-TBI. An increase in choroidal production of CCL2
was associated with a significant elevation of CCL2 con-
centration in the CSF, which was comparable to the
levels of chemokine found in the CSF of patients with
severe TBI [26].
In the contusion-injured spinal cord, Kigerl et al. [122]
reported that monocytes alternatively activated in vitro
change to classically activated cells about 7 days after
transplantation. However, it is unlikely that monocytes
are classically activated and/or change their phenotype
from alternative to classical activation since debris and
dead cells disappear and a cavity is formed after mono-
cyte infiltration [123], indicating that monocytes are al-
ternatively activated and phagocytose dead cells and
debris. Furthermore, damage does not increase further
during or after monocyte infiltration [124], an outcome
that would not be expected if monocytes were classically
activated and produced cytotoxic mediators. Damage in-
creases between 12 to 24 h after contusion-induced
spinal cord injury but does not increase thereafter [124].
Jeong et al. [125] also reported that monocytes infiltrat-
ing the injured brain and spinal cord express alternative
activation markers [108]. Even in LPS-injected brains,
microarray analyses have revealed that repair-related
genes, including those for proliferation, wound healing
and phagocytosis, increase at times corresponding to
monocyte infiltration [125]. More importantly, the dam-
aged brain is repaired after monocyte infiltration, as evi-
denced by the fact that astrocytes, blood vessels,
oligodendrocytes, myelin and neurites reappear and fill
the damaged core [125]. Monocytes appear to produce
certain chemokines that recruit astrocytes which, in
turn, extend their processes towards monocytes during
the recovery phase. For this reason, the entry of mono-
cytes into the brain is physiologically relevant for the re-
pair of damaged tissue.
After completing this reparative role, infiltrating
monocytes disappear from the damaged brain within 1
or 2 months via two different pathways. Most monocytes
die in the brain about 5 days after infiltration [125],
whilst some monocytes differentiate into resident brain
microglia [126], providing a source of monocyte-derived
microglia to replenish areas in the damaged core de-
prived by the death of resident microglia [108] (Fig. 1b).
Microglia
Microglia are highly dynamic CNS resident innate im-
mune custodians. These cells are derived from embry-
onic yolk-sac macrophages that migrate to the brain
upon the development of the cerebral vasculature [127,
128]. Microglia participate in a variety of homeostatic
CNS functions, like synaptic plasticity and learning
[129], and often respond rapidly to any inflammatory
events that occur within the CNS parenchyma [128]. Ac-
tivated microglia/macrophages release pro- and anti-
inflammatory factors that send signals to resident and
peripheral cells to promote/resolve the inflammatory re-
sponse to trauma. Chronically activated microglia/mac-
rophages have been found in rodent models and humans
after TBI [130–133] and are considered to be one of the
hallmarks of unresolved inflammation that may have
long-term repercussions [134, 135].
Peripheral microglia/macrophage phagocytic cells are
the first-line innate immune cell of the brain and make up
10% of total brain cells [136]. Following brain damage,
these cells become quickly activated by purinergic signal-
ling through the P2Y family of receptors. This leads to cell
migration from the outer area (< 75 μm in radius) into the
inner area (< 40 μm in radius) of injury [29]. Macrophages
migrate towards the damaged site whilst adjacent astro-
cytes move further away and extend their processes. Fur-
thermore, the release of ATP from damaged cells, DAMPs
and activation pathways influence immune activation after
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brain injury. High mobility group box-1 (HMGB1) protein
was found to translocate from the neuronal nucleus to the
cytoplasm in the early hours following brain injury and
localised to microglia at a later stage [137].
Due to similar origin, it is difficult to detect the presence
and functions of activated microglia versus peripheral
blood-borne macrophages that infiltrate the brain follow-
ing injury. Jin et al. [104] classified two subsets of cells
based on their degree of binding to CD45; CD45High/
CD11b + ‘macrophages’ and CD45Low/CD11b + ‘micro-
glia’. Based on these measures, CD45High/CD11b + cells
peaked within 1 day following controlled cortical impact
and remained elevated at 3 days before reaching control
levels. Jin et al., on the other hand, demonstrated that
microglia increase in numbers to a peak at day 7 post-
injury then decrease over the next week before increasing
again through 28 days [104]. These dynamics for microglia
activation are similar to those proposed by Loane and
Byrnes [90], who also cited evidence that a second peak
occurs between 30 to 60 days (Fig. 1a).
Microglial activation/polarisation
It is now established that there is significant heterogen-
eity of microglial activation in the brain. Microglia have
notable plasticity that allows them to competently re-
spond to the signals from the microenvironment and
change their phenotype and function accordingly [117,
138]. This process is called microglial polarisation which
allows the adaptive responses of innate immunity to suc-
ceed. Two conceptual microglial polarisation states have
been defined, termed M1 and M2, which denote both
ends of a continuum of functional microglia/macrophage
activation [117, 138]. The dual characters of polarised
microglia have been identified in several CNS conditions
including stroke [139], multiple sclerosis [140] and
spinal cord injury [122]. Infiltrating microglia/macro-
phages can assume neurotoxic (M1) or neuroprotective
(M2) phenotypes following traumatic brain injury. Jin
et al. [104] suggested that the brain experiences a bi-
modal surge in the microglial number after brain injury
(Fig. 3).
However, despite their different ontogeny, the specific
roles of polarised microglia (M1 and M2) in brain injury
progression and repair have not been explored fully. We
studied the cytokine response to human traumatic brain
injury and noted that TNF which is the marker of M1-
type microglia appears/peak earlier than the IL-10 (M2-
type microglia marker) [28]. According to Ransohoff
[145], the approval of this phenomenon was just an at-
tempt to simplify the interpretation of data at a time
when the evolution and functional understanding of
microglia was beginning to be understood. Henry et al.
[146] demonstrated that temporary diminution and sub-
sequent re-population of microglia during the chronic
phase of experimental brain injury decreases chronic
neuroinflammation, advances neurological recovery and
ameliorates neurodegeneration. These findings suggest
that the therapeutic window for targeting chronic neuro-
degeneration and refining functional recovery after TBI
may be more prolonged than traditionally believed [147].
Astrocytes
Astrocytes surrounding the injured region respond to
cytokines and chemokines which in turn can damage the
local neurons, and activate the surveillance microglia.
Astrocytes are activated by cell debris and inflammatory
mediators present in the milieu and can be identified as
GFAP+ (glial fibrillary acidic protein) or more appropri-
ately as ALDH1L1+ (aldehyde dehydrogenase 1 family,
member L1) cells [148].
The astrocyte was originally thought to have merely a
supportive role for brain homeostasis hence the etymol-
ogy of glia as ‘brain glue’. It has long been recognised
that astrocytes have a wider functional part to play, be-
ing responsible for upholding water and ionic balance,
the integrity of the blood-brain barrier and maintenance
of neurotransmitter homeostasis. Post TBI, astrocytes
become reactive and undergo a phenotypic change in-
cluding cellular enlargement, an extension of its pro-
cesses, and enhanced expression of GFAP. Following
brain injury, astrocytes perform critical functions but it
is not clear whether these reactive astrocytes are benefi-
cial/detrimental to the disease pathology [149]. Clear
evidence supporting a neuroprotective role of reactive
astrocytes post-TBI includes reduced neuronal staining
with NeuN or cresyl violet that correspond to areas lack-
ing GFAP+ cells [150]. Kelso and Gendelman [151] also
found a significant increase in CD45+ cells in regions
lacking reactive astrocytes, suggesting infiltration of in-
flammatory phagocytic cells. Astrocytes produce soluble
factors such as TGF-β and prostaglandins which might
inhibit microglial activation [152–156]. Ji and coworkers
[157] have demonstrated that uncharacterised soluble
factor(s) released from astrocytes induce the expression
of antioxidant enzymes, which in turn inhibit microglial
activation. In the injured brain, astrocytes rapidly-
produce anti-inflammatory molecules, which could be
one of the mechanisms for reversing microglial activa-
tion in TBI. Furthermore, astrocytes support neuronal
survival by providing growth factors and nutrients to
neurons and maintaining homeostasis of extracellular
fluid by boosting glutamate and potassium uptake. Jeong
et al. [125] reported that the functional loss and/or death
of astrocytes preceded secondary neuronal death in
spinal cord injury. Based on these findings, Jeong et al.
[125] propose that the loss of astrocyte function might
be caused by secondary brain injury.
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We recently reported how in vitro human astrocyte
cultures react to cytokines across a concentration range
that approximates the outcome of human TBI [19]. Ex-
perimentally, enriched cultures of human-induced pluri-
potent stem cell (iPSC)-derived astrocytes were exposed
to IL-1β (1-10,000 pg/mL), IL-4 (1-10,000 pg/mL), IL-6
(100-1,000,000 pg/mL), IL-10 (1-10,000 pg/mL) and TNF
(1-10,000 pg/mL). Cultures were fixed and immune-
labelled at different time points (1, 24, 48 and 72 h), and
the secretome was analysed using a human cytokine/
Fig. 3 Graphical representation of the cellular response and brain damage post-TBI, including the proposed microglia (M1 and M2) and astrocytes (A1 and A2)
dynamics over time. a Injury to the brain may cause cell membrane disruption, vascular rupture and BBB damage. This leads to the release of DAMPs, cytokines,
chemokines immediately after injury and peaks within minutes to hours and continue to release by the damaged tissue and infiltrating cells. This causes the
activation of microglia and astrocytes and recruitment of circulating immune cells. These immune responses are largely overlapped (Fig. 1). The inflammatory
response is the key to debris clearance, repair and regeneration post-TBI. But skewed inflammation might lead to secondary brain injury. The role of microglial
activation is increasingly recognised as both a critical pathological mechanism and therapeutic target. Specifically, there is a shift from a dominance of M2
(neuroprotective) microglia into a preponderance of M1 (neurotoxic) microglia [141]. M1:M2 microglia population ratio shifts from 1:5 (day 1) to 7.5:1 (day 7)
following injury [142]. Also, Wang et al. [143] whilst working with CCI mice model discovered that the phenotypic ratio of M1 and M2 at 48 h (day 2) is 1:3 and
the M2-like microglia/macrophages peaked at day 5 but decreased rapidly thereafter. b Both microglia and astrocytes are highly sensitive to their environment.
Unlike other inflammatory cells, astrocytes and microglia are in a constant dynamic mode. Their subtypes will shift with time and space, and with other
unknown variables. Microglia and astrocytes so far have been shown to exist in two distinct reactive states (Microglia, M1-neurotoxic and M2-neuroprotective;
Astrocytes, A1-neurotoxic and A2-neuroprotective). Considering these two states, it is possible that they exist as a continuum, with a heterogeneous mixed
population in the middle. It should be noted that this classification is somewhat limited because microglia/macrophages can exhibit more than two canonical
polarisation states [144]. In much a similar way, reactive astrocytes might have more than two polarised states. The heterogeneity of reactive microglia and
astrocytes need to be investigated thoroughly
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chemokine 39-plex Luminex assay [19]. Results showed
that the exposure of IL-1β causes the most profound
downstream response and TNF, IL-6 had intermediate
responses, whilst IL-4 and IL-10 only led to weak re-
sponses over time and/or increasing concentrations.
We also reported that expression of IL-1β, IL-6 and
TNF receptor mRNA was higher in astrocyte than in
neuronal cultures. Various secreted cytokines had
temporal trajectories, which corresponded to those
seen post-human-TBI.
Astrocyte activation/polarisation
Analogous to microglial polarisation states, it has been
suggested that neuroinflammation can stimulate two types
of astrocytes, A1 and A2 (Fig. 3b). Liddelow and Barres
[158] recently postulated that astrocytes can switch in a
stimulus-specific manner towards a classical pro-
inflammatory (harmful) A1-phenotype or an alternative
anti-inflammatory (beneficial) A2-phenotype. This mirrors
the classical and alternative states seen in microglia. Al-
though we have noted earlier that microglial signalling
regulates astrocyte functions [159], both the stimulus and
the physiological mechanisms leading to the transform-
ation of astrocytes remain unclear. Transcriptome-wide
analyses of astrocytes showed that A1-reactive (neuroin-
flammatory) astrocytes stimulate many complement cas-
cade genes that have been previously known to be
detrimental to synapses, implying that A1 astrocytes might
have harmful effects. On the contrary, A2 reactive
astrocytes stimulates numerous neurotrophic factors pro-
moting growth and survival of neurons, and thrombos-
pondins, which in turn promotes synaptic repair. This
stimulation suggests that A2 astrocytes might have benefi-
cial functions [160, 161].
Recently, Neal et al. [162] discovered that PK2(proki-
neticin 2)-induced astrocyte reactivity leads to an in-
crease in antioxidant and anti-inflammatory proteins
with increasing glutamate uptake resulting in decreased
inflammatory factors. Furthermore, Ma and colleagues
[163] whilst working on SAH (subarachnoid haemor-
rhage)-induced early brain injury added that administra-
tion of rPK2 (recombinant PK2) or augmenting PK2
expression may stimulate a modulation of astrocytic po-
larisation towards a more protective (A2-type) pheno-
type. On the other hand, Miyamoto et al. [164]
suggested that prolonged cerebral hypoperfusion leads
to impaired oligodendrocyte maturation which, in turn,
increases A1-type astrocytes number. Whilst working
with the rat primary cells cocultured with a nonlethal
concentration of CoCl2, they observed that at 28 days
after hypoperfusion, the number of astrocytes increased
and oligodendrocyte decreased. Interestingly, increased
astrocytes were mainly A1-like astrocytes; however, the
number of A2-like type decreased. Thus, ligands central
to either the A1-reactive (proinflammatory) state or A2-
reactive (protective) state may serve as potential thera-
peutic agents for a number of neurodegenerative dis-
eases in the future.
Neurons
Neurons present in the injured region experience mech-
anical forces at dendrites, cell body, axon and are recog-
nised in tissue sections as NeuN+ cells. Force
transmission to the head with or without direct impact
leads to it stretching, bending or shearing. The axonal
injury associated with TBI can be seen at deep sites at
the junction between grey and white matter, particularly
in the corpus callosum. In addition to primary injury,
the secondary injury phase also causes damage to the
neurons by excitotoxic compounds and inflammatory
mediators present in the extracellular space. Interaction
of neurons with microglia and astrocytes is a key factor
for inhibiting unwarranted microglial activation [165].
Neurons inhibit microglial inflammatory responses via
expression of ligands (e.g. CD200 and fractalkine), whose
receptors are expressed in microglia [166]. Consistent
with this, Cardona and colleagues proved that brain in-
flammation is significantly enhanced in fractalkine
receptor-knockout mice [167]. Therefore, neurons in-
hibit microglial activation in the intact brain [168].
In a cell culture model of neuronal reactivity, one of
our recent papers, we witnessed the production of differ-
ent patterns of cytokines in enriched human cortical
neuronal cultures after cytokine induction which might
alter the pathophysiological processes potentially in both
beneficial and detrimental ways in the in vivo state [18].
Our main focus was to elucidate the secondary cytokine
responses to primary known pro-inflammatory cytokine
exposure, and we validated the data clinically against
cytokine patterns seen post-TBI. We overcome the in-
accessibility to human neuronal models by exploiting di-
rected differentiation of human pluripotent stem cells,
which represent a reductionist, and clinically relevant
and reliable model system. Further, in the absence of
glia, it has been shown that IL-1β is not directly toxic to
neuronal cells, suggesting that neurons may not be the
primary target of IL-1β [169, 170]. Deshpande et al.
[169] in their paper showed induced neuronal death in
IL-1β treated astrocytic-culture supernatant on a human
foetal neuron culture. Furthermore, in human foetal
neuronal-glial co-culture model, IL-1β and TNF did not
show neurotoxic effects in isolation but triggered neur-
onal death in combination [171]. Likewise, induction of
TNF produces the synergistic neurotoxic effect of IL-1β
and IFN-γ. To sum up, IL-1β exposure did not produce
the same degree of cytokine generation as IL-6 and
TNF, which might be due to the enriched neuronal
monoculture paradigm.
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Adaptive immune response
The adaptive immune response consists of two parts: (i)
humoral immunity and (ii) cell-mediated immunity.
Humoral immunity is mediated by B-lymphocytes and is
responsible for the production of antibodies following ac-
tivation by an antigen. Cell-mediated immunity is primar-
ily directed by activated memory effector T-lymphocytes
or regulatory cells and can have destructive or homeo-
static effects. These responses can be activated as a result
of protein modifications that result from brain injury and
lead to chronic neurodegeneration [172, 173].
B cells
B-lymphocytes arise from progenitors in the bone mar-
row and enter the circulation, ultimately forming nests
in the spleen and lymph nodes. Following activation by a
pathogen, they differentiate into plasma cells whose pri-
mary function is to produce antibodies. Involvement of
B cells following brain injury has not been studied in
great details as compared to the other aspects of im-
munity. OX33, a B cell marker has been reported 4 to 6
days after experimental injury [174]. Meissner A et al.
[175] showed that a chemokine associated with B cell
chemotaxis (CCL20) is elevated within 4 h and persists
out to 3 days following experimental brain injury (CCI)
[176]. Few clinical studies have also been conducted to
determine the effect of brain injury on B cell popula-
tions. Mrakovcic-Sutic I et al. [177] investigated B cell
(CD5+/CD19+) populations in the peripheral blood of
20 patients with severe TBI and found no significant dif-
ference when compared to healthy controls.
Until recently, TBI was thought to have no impact
upon B-cell biology, an idea based on a handful of ex-
perimental studies that had shown no alterations in the
occurrence, number or proliferative capacity of B cells
following brain injury [114, 177–180]. But more recently,
studies performed by two groups of scientists [181, 182]
demonstrated that autoantibodies specific for CNS pro-
teins were detected in the serum of brain injury patients,
suggesting that tolerance is broken and B cells initiate
an immune response against brain-derived antigens fol-
lowing injury. Marchi et al. [181] uncovered that serum
levels of the astrocytic protein (S100B) were higher in
subjects with experienced frequent sub-concussive head
hits (SHH) accompanied by an elevated level of anti-
S100B auto-antibodies. Increased S100B auto-antibody
was linked with low cognitive functions, and these auto-
antibodies reacted strongly towards epitopes of both the
glial and neuronal cells. It was believed that the produc-
tion of auto-antibodies against nervous system-residing
proteins may serve as a risk factor for premature neuro-
degeneration in repeated SHH [181]. Similar to this,
Zhang et al. [182] identified auto-antibodies against the
astrocyte-residing transitional filament protein GFAP
and its breakdown products obtained from patients fol-
lowing severe TBI in serum samples. These GFAP auto-
antibodies, which were detected as quickly as 4 days
post-injury and whose range positively correlated with
GCS (Glasgow Coma Scale) scores suggesting a potential
pathophysiological duty for B cells during the recovery
phase of brain injury [182]. It is now established by dif-
ferent studies that in both acute and chronic post-TBI,
AutoAb [GFAP] is useful to study the dynamic interac-
tions amongst brain autoimmune mechanisms. The im-
portant new finding reported by Wang et al. [183] in
their study suggested that in acute TBI, plasma AutoAb
[GFAP] levels correlate with a history of past TBI expos-
ure. Cox and colleagues [184] hypothesised that the ex-
posure of lymphocytes to abnormally large quantities of
myelin antigens would kindle proliferation of myelin
specific lymphocytes. They validated a substantial in-
crease in the number of myelin-specific auto-reactive
lymphocytes, and the degree to which they multiply,
after TBI. These data for the first time reported that
autoreactive T cell responses directed at myelin antigens
occur in human brain injury.
T cells
Brain injury (severe TBI) results in a significant decline
in the percentage and an absolute number of circulating
T lymphocytes [114, 185]. Mrakovcic-Sutic et al. [177]
detected that this decline within 24 h of injury and on
day 4 post-injury, is the result of a considerable reduc-
tion in both CD4+ T helper cells and CD8+ cytotoxic T
cells. Presently, the mechanism(s) underlying TBI-
induced drop of the circulating T-cell pool is not fully
clear. After a series of in vivo experiments, Nakai et al.
reported that administration of B2-adrenergic receptor
(B2AR) agonists is followed by a rapid decrease of blood
CD4+ and CD8+ T cells. With further investigations,
they revealed that this lymphopenia was the result of
B2AR stimulation inhibiting lymphocyte departure from
lymph nodes [186]. Given that TBI results in elevated
levels of circulating catecholamines [187, 188], then
lymphocyte retention in lymph nodes may be one of the
mechanisms which explain the significant reduction in
circulating T cells that have been witnessed following
brain injury.
Generally, human studies have supported the pre-
clinical confirmation of T cell recruitment following
brain injury. Holmin et al. [189] performed an analysis
of brain biopsy and tissue collected from TBI victims at
different time points post-injury. This study assessed the
percentage of patients who had immunohistochemical
evidence of inflammatory cells present in the tissue sam-
ple. The authors could not identify CD3+, CD4+ or
CD8+ T cells in brain biopsies collected within 24 h fol-
lowing brain injury. However, all brain samples collected
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3 to 5 days post-trauma had some expression of CD3+
and CD4+ cells, and 75% of the samples had CD8+ cells.
Whilst this pattern supports pre-clinical evidence of late
involvement, it should be noted that the injuries did not
happen in the same area for all patients and that this
study included only 12 patients, 4 of which were in the 3
to 5-day group [189]. One study investigating 56 post-
mortem, TBI cases found CD3+ T cells in the lesion
area after 4 days post-injury and persisted for at least 26
days [105], but they did not assess T cell subsets by pin-
pointing any other markers.
Conclusion
Cellular infiltration in TBI is a complex process involving
several types of cells and soluble mediators, including
DAMPs, cytokines, chemokines, neutrophils, monocytes,
microglia, astrocytes and neurons. Microglia continuously
survey the brain to identify any structural abnormalities in
neurons. In response to brain trauma, microglia at the injury
penumbra quickly isolate the damaged core region and pre-
vent the spread of the unsettled injury microenvironment to
surrounding regions. Then, there are neutrophil infiltrates to
protect the region from further infection. To repair the dam-
aged brain, monocytes infiltrate the injured site and peak
around 3-5 days post-injury. We suggest that the secondary
injury (brain damage) that exacerbates acute injury may be
caused by the secondary activation of M1-like (neurotoxic)
microglia. Hence, a detailed understanding of cellular and
molecular mechanisms, and implementation of reductionist
models [18, 19] for the acute and chronic TBI phases, will
serve to advance our understanding and management of
TBI. A mechanistic understanding of primacy and roles of
the various cells present in response to injury (which can be
termed ‘the cellular phase’ of TBI) might prove transform-
ational in identifying promising therapeutic targets within a
wider time window for potential intervention in a majority of
the frequently devastating cases of TBI.
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